Genome-Wide mRNA Expression Analysis of Hepatic Adaptation to High-Fat Diets Reveals Switch from an Inflammatory to Steatotic Transcriptional Program

Background Excessive exposure to dietary fats is an important factor in the initiation of obesity and metabolic syndrome associated pathologies. The cellular processes associated with the onset and progression of diet-induced metabolic syndrome are insufficiently understood. Principal Findings To identify the mechanisms underlying the pathological changes associated with short and long-term exposure to excess dietary fat, hepatic gene expression of ApoE3Leiden mice fed chow and two types of high-fat (HF) diets was monitored using microarrays during a 16-week period. A functional characterization of 1663 HF-responsive genes reveals perturbations in lipid, cholesterol and oxidative metabolism, immune and inflammatory responses and stress-related pathways. The major changes in gene expression take place during the early (day 3) and late (week 12) phases of HF feeding. This is also associated with characteristic opposite regulation of many HF-affected pathways between these two phases. The most prominent switch occurs in the expression of inflammatory/immune pathways (early activation, late repression) and lipogenic/adipogenic pathways (early repression, late activation). Transcriptional network analysis identifies NF-κB, NEMO, Akt, PPARγ and SREBP1 as the key controllers of these processes and suggests that direct regulatory interactions between these factors may govern the transition from early (stressed, inflammatory) to late (pathological, steatotic) hepatic adaptation to HF feeding. This transition observed by hepatic gene expression analysis is confirmed by expression of inflammatory proteins in plasma and the late increase in hepatic triglyceride content. In addition, the genes most predictive of fat accumulation in liver during 16-week high-fat feeding period are uncovered by regression analysis of hepatic gene expression and triglyceride levels. Conclusions The transition from an inflammatory to a steatotic transcriptional program, possibly driven by the reciprocal activation of NF-κB and PPARγ regulators, emerges as the principal signature of the hepatic adaptation to excess dietary fat. These findings may be of essential interest for devising new strategies aiming to prevent the progression of high-fat diet induced pathologies.

[1]  J. Kramer,et al.  Ectonucleoside Triphosphate Diphosphohydrolase Type 5 (Entpd5)-Deficient Mice Develop Progressive Hepatopathy, Hepatocellular Tumors, and Spermatogenic Arrest , 2009, Veterinary pathology.

[2]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[3]  F. Tinahones,et al.  Fat overload aggravates oxidative stress in patients with the metabolic syndrome , 2008, European journal of clinical investigation.

[4]  R. Medzhitov Origin and physiological roles of inflammation , 2008, Nature.

[5]  F. Gonzalez,et al.  Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. , 2008, Cell metabolism.

[6]  A. Alcamí,et al.  NF-κB-Mediated Activation of the Chemokine CCL22 by the Product of the Human Cytomegalovirus Gene UL144 Escapes Regulation by Viral IE86 , 2008, Journal of Virology.

[7]  T. Luedde,et al.  Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[8]  C. Glass,et al.  Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. , 2007, Trends in immunology.

[9]  Age K Smilde,et al.  Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis , 2007, Genome Biology.

[10]  C. Glass,et al.  PPARs and molecular mechanisms of transrepression. , 2007, Biochimica et biophysica acta.

[11]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[12]  J. Schölmerich,et al.  High‐fat Diets: Modeling the Metabolic Disorders of Human Obesity in Rodents , 2007, Obesity.

[13]  T. Luedde,et al.  Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .

[14]  B. Staels,et al.  Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[15]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[16]  D. Brenner,et al.  Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis , 2006, Hepatology.

[17]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[18]  Wenxuan Zhong,et al.  A data-driven clustering method for time course gene expression data , 2006, Nucleic acids research.

[19]  Ramón Díaz-Uriarte,et al.  Gene selection and classification of microarray data using random forest , 2006, BMC Bioinformatics.

[20]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[21]  T. Okumura,et al.  Increased expression of PPARγ in high fat diet-induced liver steatosis in mice , 2005 .

[22]  R. Frants,et al.  Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. , 2005, Atherosclerosis.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .

[25]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[26]  B. Teusink,et al.  Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. , 2005, Journal of lipid research.

[27]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[28]  M. Miyazaki,et al.  Reduced Adiposity and Liver Steatosis by Stearoyl-CoA Desaturase Deficiency Are Independent of Peroxisome Proliferator-activated Receptor-α* , 2004, Journal of Biological Chemistry.

[29]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[30]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[31]  P. Kopelman,et al.  New thoughts on managing obesity , 2004, Gut.

[32]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[33]  P. Quax,et al.  Toll-Like Receptor 4 Is Involved in Outward Arterial Remodeling , 2004, Circulation.

[34]  M. O’connor,et al.  Peroxisome Proliferator Activator Receptor-γ Ligands, 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways 1 , 2003, The Journal of Immunology.

[35]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[36]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[37]  J. Saurat,et al.  Peroxisome proliferator‐activated receptors in cutaneous biology , 2003, The British journal of dermatology.

[38]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[39]  Sam J. P. Gobin,et al.  Regulation of human β2-microglobulin transactivation in hematopoietic cells , 2003 .

[40]  S. Kersten,et al.  Nutrigenomics: goals and strategies , 2003, Nature Reviews Genetics.

[41]  Kunihiro Matsumoto,et al.  Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade , 2003, Nature Cell Biology.

[42]  F. Gonzalez,et al.  Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-activated Receptor γ1 (PPARγ1) Overexpression* , 2003, The Journal of Biological Chemistry.

[43]  P. C. Chin,et al.  Akt Is a Downstream Target of NF-κB* , 2002, The Journal of Biological Chemistry.

[44]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[45]  R. Monteiro,et al.  Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-kappaB. , 2002, American journal of respiratory cell and molecular biology.

[46]  A. Batlle,et al.  The effects of some porphyrinogenic drugs on the brain cholinergic system. , 2002, Cellular and molecular biology.

[47]  J. Seidell,et al.  Epidemiology of obesity. , 2002, Seminars in vascular medicine.

[48]  N. Datson,et al.  Identification of Differentially Regulated Genes in Mildly Hyperlipidemic ApoE3-Leiden Mice by Use of Serial Analysis of Gene Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[49]  W. Hsueh,et al.  Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[50]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[51]  S. Lin,et al.  Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice , 2000, International Journal of Obesity.

[52]  C. Glass,et al.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Kopelman Obesity as a medical problem , 2000, Nature.

[54]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[55]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[56]  Michael Karin,et al.  The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation* , 1999, The Journal of Biological Chemistry.

[57]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[58]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[59]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[60]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  G. Courtois,et al.  Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation , 1998, Cell.

[62]  L. Havekes,et al.  Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. , 1997, Atherosclerosis.

[63]  J. Egido,et al.  Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. , 1997, Journal of immunology.

[64]  A. Koj Initiation of acute phase response and synthesis of cytokines. , 1996, Biochimica et biophysica acta.

[65]  B. Spiegelman,et al.  Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.

[66]  B. Spiegelman,et al.  ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. , 1996, Genes & development.

[67]  K. Ozato,et al.  Interferon regulatory factor-2 physically interacts with NF-κB in vitro and inhibits NF-κB induction of major histocompatibility class I and β2-microglobulin gene expression in transfected human neuroblastoma cells , 1995, Journal of Neuroimmunology.

[68]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[69]  L. Lissner,et al.  Dietary fat and obesity: evidence from epidemiology. , 1995, European journal of clinical nutrition.

[70]  R. Frants,et al.  Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. , 1994, The Journal of clinical investigation.

[71]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.

[72]  J. Jukema,et al.  Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). , 2008, Critical care medicine.

[73]  T. Luedde,et al.  Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. , 2007, Cancer cell.

[74]  Y. Terauchi,et al.  Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. , 2007, Internal medicine.

[75]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[76]  Bradley E. Enerson,et al.  Bioinformatics Original Paper Pathway Analysis Using Random Forests Classification and Regression , 2022 .

[77]  T. Okumura,et al.  Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. , 2005, Biochemical and biophysical research communications.

[78]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. , 2005, Nature medicine.

[79]  M. Hofker,et al.  Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice , 2005, Clinical chemistry and laboratory medicine.

[80]  Kunihiro Matsumoto,et al.  Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. , 2003, Nature cell biology.

[81]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[82]  J. Reddy,et al.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. , 2003, The Journal of biological chemistry.

[83]  P. J. van den Elsen,et al.  Regulation of human beta 2-microglobulin transactivation in hematopoietic cells. , 2003, Blood.

[84]  P. C. Chin,et al.  Akt is a downstream target of NF-kappa B. , 2002, The Journal of biological chemistry.

[85]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[86]  J. Romashkova,et al.  NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.

[87]  G. Courtois,et al.  Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. , 1998, Cell.

[88]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[89]  K. Ozato,et al.  Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. , 1995, Journal of neuroimmunology.

[90]  G. Reaven,et al.  Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. , 1974, The Journal of clinical investigation.